ORIC Pharmaceuticals Reports Q3 2025 Financial Results

Oric Pharmaceuticals Inc ( (ORIC) ) has released its Q3 earnings. Here is a breakdown of the information Oric Pharmaceuticals Inc presented to its investors.

ORIC Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to overcome resistance in cancer, operating primarily in the United States. In its latest earnings report for the quarter ended September 30, 2025, ORIC Pharmaceuticals highlighted its strategic pipeline prioritization, focusing on advancing its lead clinical programs, ORIC-944 and enozertinib, while reducing its workforce by approximately 20% to streamline operations.

The company reported a net loss of $32.6 million for the third quarter of 2025, a slight improvement from the $34.6 million loss in the same period last year. Total operating expenses were $36.7 million, driven by research and development costs of $28.8 million and general and administrative expenses of $7.9 million. Despite these losses, ORIC Pharmaceuticals successfully raised $108.7 million through an at-the-market offering, contributing to a strong cash position of $49.7 million and short-term investments of $237.5 million.

ORIC Pharmaceuticals continues to leverage strategic collaborations, including agreements with Johnson & Johnson and Bayer, to evaluate its product candidates in combination with established therapies. These partnerships are crucial for the company’s development strategy, allowing it to maintain full economic ownership and control of its lead programs while benefiting from the resources and expertise of its partners.

Looking ahead, ORIC Pharmaceuticals remains committed to advancing its clinical programs and achieving key development milestones. The company’s management is optimistic about its financial position and believes it has sufficient resources to fund operations for at least the next twelve months, positioning it well for future growth and development in the biopharmaceutical sector.